

BOSTON SCIENTIFIC CORP  
Form 8-K  
March 12, 2007

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): March 12, 2007

**BOSTON SCIENTIFIC CORPORATION**  
(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other  
jurisdiction of  
incorporation)

**1-11083**  
(Commission  
file number)

**04-2695240**  
(IRS employer  
identification no.)

**One Boston Scientific Place, Natick, Massachusetts**  
(Address of principal executive offices)

**01760-1537**  
(Zip code)

Registrant's telephone number, including area code: **(508) 650-8000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 8.01.**

**OTHER EVENTS.**

On March 12, 2007, Boston Scientific Corporation (the “Company”) issued a press release announcing that the Company’s Board of Directors has authorized management to explore an initial public offering (IPO) of a minority interest in its Endosurgery group. An IPO would involve Boston Scientific selling approximately 20 percent of the Endosurgery group and establishing a separately traded public company. The new company would remain a majority-owned subsidiary of Boston Scientific. The press release is attached hereto as Exhibit 99.1.

**ITEM 9.01.**

**FINANCIAL STATEMENTS AND EXHIBITS.**

99.1 Press Release issued by Boston Scientific Corporation dated March 12, 2007.

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BOSTON SCIENTIFIC CORPORATION**

Date: March 12, 2007

By: /s/ Lawrence J. Knopf

\_\_\_\_\_  
Lawrence J. Knopf  
Vice President and Assistant General Counsel

**INDEX TO EXHIBITS**

**Exhibit  
Number**

**Description**

99.1

Press Release dated March 12, 2007.